TABLE 1

FROM:

Androgen Receptor Alterations in Prostate Cancer Relapsed during a Combined Androgen Blockade by Orchiectomy and Bicalutamide

Kyllikki Haapala, Eija-R Hyytinen, Mikko Roiha, Marita Laurila, Immo Rantala, Heikki J Helin and Pasi A Koivisto

Table 1. Clinicopathological Characteristics and Androgen Receptor Gene Aberrations of the Orchiectomy+Bicalutamide-Refractory Prostate Cancers

Sample	TNM	WHO grade	Gleason's score	Treatment	Therapy response (mo)	AR mutation	AR amplification
1	T4NXM0	III	10	ORCH+BICALUTAMIDE	6	wt	No
2a	T2NXM1	III	9	ORCH+BICALUTAMIDE	20	wt	No
2b		III	10	ORCH+BICALUTAMIDE+IPHOSPHAMIDE	11	732 Asp (GAC) Asp (GAT)	No
3	T4NXM0	II	7	ORCH+BICALUTAMIDE	13	wt	No
4	T4NXM0	III	10	ORCH+BICALUTAMIDE	50	166 Gly (GGC) Ser (AGC)	No
5	T4NXM1	II	7	ORCH+BICALUTAMIDE	94	wt	No
6	T4N1M0	III	10	ORCH+BICALUTAMIDE	13	741 Trp (TGG) Cys (TGT)	No
7	T4NXM0	III	10	ORCH+BICALUTAMIDE	14	749 Met (ATG) Ile (ATA)	No
						867 Gln (CAG) Gln (CAA)
8a	T4NXM0	III	9	ORCH+BICALUTAMIDE	49	wt	No
8b		III	9	ORCH+BICALUTAMIDE+BISPHOSPHONATE CLODRONATE	52	wt	No
8c		III	9	ORCH+BICALUTAMIDE+IPHOSPHAMIDE	54	wt	No

 TNM of the primary tumor (T = tumor, N = node, M = metastasis); WHO, World Health Organization; AR, androgen receptor; ORCH, orchiectomy; wt, wild type.